Tofacitinib: A Review of its Use in Adult Patients with Rheumatoid Arthritis

Biologic Agents in Rheumatoid Arthritis: An Update for Managed Care Professionals

(2016) Sandeep K. Agarwal   JOURNAL OF MANAGED CARE PHARMACY

THU0131 Tofacitinib (CP-690,550), an oral janus kinase inhibitor: Analysis of malignancies across the rheumatoid arthritis clinical programme

(2014) X. Mariette et al.   ANNALS OF THE RHEUMATIC DISEASES

Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study*

(2013) Iain B McInnes et al.   ANNALS OF THE RHEUMATIC DISEASES

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study

(2013) Désirée van der Heijde et al.   ARTHRITIS AND RHEUMATISM

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

(2013) Gerd R Burmester et al.   LANCET

In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis

(2012) Y Tanaka et al.   ANNALS OF THE RHEUMATIC DISEASES

Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data

(2012) Pankaj Gupta et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

(2012) Apostolos Kontzias et al.   CURRENT OPINION IN PHARMACOLOGY

Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy

(2012) Maria A. Lopez-Olivo et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

Strategies for the Management of Rheumatoid Arthritis

(2012) W.S. Wilkie et al.   ORTHOPEDICS

2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

(2012) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

AJAK inhibitor, tofacitinibreduces IL-6 and matrix metalloproteinase-3 productionin rheumatoid arthritis with suppressed cartilage destruction

(2012) Kunihiro Yamaoka et al.   ARTHRITIS RESEARCH & THERAPY

Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response

(2011) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon

(2011) Sanna Rosengren et al.   ANNALS OF THE RHEUMATIC DISEASES

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

(2011) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

(2011) Roy Fleischmann et al.   ARTHRITIS AND RHEUMATISM

The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells

(2011) Keisuke Maeshima et al.   ARTHRITIS AND RHEUMATISM

Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)

(2011) Kamran Ghoreschi et al.   JOURNAL OF IMMUNOLOGY

Influence of Janus Kinase Inhibition on Interleukin 6-mediated Induction of Acute-phase Serum Amyloid A in Rheumatoid Synovium

(2011) K. MIGITA et al.   JOURNAL OF RHEUMATOLOGY

The Pathogenesis of Rheumatoid Arthritis

(2011) Iain B. McInnes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate

(2011) Yoshiya Tanaka et al.   ARTHRITIS CARE & RESEARCH

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Treating rheumatoid arthritis to target: recommendations of an international task force

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection

(2010) Mark E. Flanagan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Rheumatoid arthritis

(2010) David L Scott et al.   LANCET

Anti-tumor necrosis factor therapy and cancer risk in patients with autoimmune disorders

(2010) Karen B. Onel et al.   ARTHRITIS CARE & RESEARCH

Editorial

(2010) Alejandro Balsa et al.   Therapeutic Advances in Musculoskeletal Disease

Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial

(2009) J H Coombs et al.   ANNALS OF THE RHEUMATIC DISEASES

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

(2009) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment

(2009) Stanley Cohen et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY

Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis

(2008) Anthony J Milici et al.   ARTHRITIS RESEARCH & THERAPY